Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
In current study, we analyzed the carbohydrate structure of anti-CD20 monoclonal antibody rituximab to evaluate effect of glycosylation on the efficacy and the pharmacokinetics of antibody preparation. Several glycan species were identified in rituximab. The relative content of glycoforms changed in a time-dependent mannar. These changes affected to pharmacokinetics of rituximab. In conclusion, we obtained novel findings in the role of carbohydrate of rituximab.
|